The gvhd Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the gvhd Hub cannot guarantee the accuracy of translated content. The gvhd and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View gvhd content recommended for you
Positive results for cannabidiol (CBD) for the prevention of acute graft-versus-host disease (GvHD)
On August 19th 2019, it was announced that interim results from the phase II clinical study (NCT03840512) evaluating cannabidiol (CBD) for the prevention of acute graft-versus-host disease (GvHD) were significantly positive. As a result, enrollment into the high-dose cohort of the phase II trial will not commence, and instead, a phase III clinical registration study will be initiated. Furthermore, CBD has been granted orphan drug designation by both, the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA). Also, the FDA has recommended the application for both Breakthrough Therapy and Fast Track Designations for CBD for the prevention and treatment of acute GvHD.1
The phase II study evaluated the pharmacokinetic profile, safety, and efficacy of multiple doses of CBD in combination with standard prophylaxis (cyclosporine and methotrexate) for the prevention of acute GVHD (aGVHD) in patients following allogeneic hematopoietic stem cell transplantation (HSCT).3
Phase II results after 180 days of observation:
- 1 of 12 patients in 75 mg cohort (8%) developed grade 2–4 acute GvHD, while no patients developed grades 3 or 4 acute GvHD
- No patients developed grades 2–4 acute GvHD in the medium-dose cohort (150 mg dose of CBD)
Principal elements of the phase III study design will include the following:
Phase III of the study will be a multicenter (Australia and Israel), double-blind placebo-controlled clinical trial. In this trial, 50 patients will be enrolled, 25 patients will be given a 150 mg dose of CBD and 25 patients will be given placebo, twice daily.
References